title: Vemurafenib-induced eccrine squamous syringometaplasia.
abstract: We report herein a patient treated with vemurafenib for a stage IV melanoma who developed an eruption related to eccrine squamous syringometaplasia (ESS). This entity is a well-described side effect of cytostatic therapies used for malignant neoplasia and is clinically characterized by a symmetric cutaneous eruption composed of papules and vesicles preferentially located on fold and intertriginous areas. It is histologically defined by a squamous metaplasia of eccrine ductal epithelium. ESS represents another skin eruption to be added to the list of cutaneous adverse events associated with vemurafenib, a selective BRAF inhibitor used to treat patients with metastatic melanoma harboring the V600E mutation. The discussion focuses on the pathogenesis of ESS secondary to vemurafenib and on alternative diagnoses.
authors.affiliation: Department of Dermatology, Rennes-1 University Hospital, Rennes, France.
authors.forename: A
authors.initials: A
authors.lastname: Lescoat
authors.forename: C
authors.initials: C
authors.lastname: Droitcourt
authors.forename: N
authors.initials: N
authors.lastname: Stock
authors.forename: F
authors.initials: F
authors.lastname: Le Gall
authors.forename: A
authors.initials: A
authors.lastname: Dupuy
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004439:Eccrine Glands / Q000473:pathology*; D004847:Epithelial Cells / Q000473:pathology*; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008679:Metaplasia / Q000139:chemically induced / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib